As of June 5, 2025, Merck & Co Inc (MRK) reports a Forward P/E of 8.31.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing Merck & Co Inc's Forward P/E to Peers
To better understand Merck & Co Inc's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| Merck & Co Inc (MRK) | 8.31 |
| Catalent Inc (CTLT) | 55.81 |
| Corcept Therapeutics Inc (CORT) | 50.52 |
| Eli Lilly and Co (LLY) | 33.87 |
| Innoviva Inc (INVA) | 29.76 |
| Zoetis Inc (ZTS) | 26.44 |
Compared to its competitors, Merck & Co Inc's Forward P/E is about average compared to peers, indicating growth expectations in line with industry peers.